Astellas, Amgen to pay $124.75M for False Claims Act violations
By 
Jaclyn Jaeger2019-04-26T20:03:00
Pharmaceutical companies Astellas and Amgen will pay a total of $124.75 million to resolve allegations that they violated the False Claims Act by illegally paying the Medicare co-pays for their own high-priced drugs.
More from Regulatory Enforcement
-
News BriefHong Kong securities regulator hits repeat offender Deutsche Bank with $3M fine
Deutsche Bank has agreed to pay a $3 million fine and has returned $5 million in fee overcharges to customers as part of a resolution with Hong Kong’s financial services regulator.
-
News BriefDOJ, SEC charge owner of Pennsylvania companies of running $770M Ponzi scheme
The majority owner of a Pennsylvania investment firm faces 100 years of prison time and huge fines for allegedly running a $770 million Ponzi scheme centered on an ATM company he also owned.
-
ArticleDisney hit with $10M FTC fine for allegedly collecting children’s data
The Federal Trade Commission (FTC) proposed an enforcement action against Disney for allegedly collecting personal information about children, and then threw salt in the wound by calling the company out in an alert emailed to an untold number of businesses.